MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Ataxia: Treatment"

  • 2024 International Congress

    Safety and Efficacy of Vatiquinone Treatment in Friedreich Ataxia Patients from MOVE-FA: a Phase 3, Double-blind, Placebo-controlled Trial

    D. Lynch, A. Duquette, M. França Jr, S. Perlman, A. Durr, E. Bertini, A. Darling, K. Mathews, L. Schöls, A. Fournier, M. Delatycki, S. Subramony, R. Roxburgh, O. Zhang, C. Rummey, A. Salvucci, B. Yao, J. Cherry, L. Golden, T. Zesiewicz (Philadelphia, USA)

    Objective: Describe the results of vatiquinone from MOVE-FA (NCT04577352), the 72-week placebo-controlled phase 3 study of patients with Friedreich Ataxia (FA). Background: FA, the most…
  • 2024 International Congress

    Improvement in Upright Stability subscale of mFARS with Vatiquinone Treatment in MOVE-FA: a Phase 3, Double-blind, Placebo-controlled Trial

    D. Lynch, A. Duquette, M. França Jr, S. Perlman, A. Durr, E. Bertini, A. Darling, K. Mathews, L. Schöls, A. Fournier, M. Delatycki, S. Subramony, R. Roxburgh, O. Zhang, C. Rummey, A. Salvucci, B. Yao, J. Cherry, L. Golden, T. Zesiewicz (Philadelphia, USA)

    Objective: Describe the results of vatiquinone on the Upright Stability Subscale (USS) from MOVE-FA (NCT04577352), the 72-week placebo-controlled phase 3 study of patients with Friedreich…
  • 2024 International Congress

    Deep Brain Stimulation of bilateral ventral intermediate nucleus in a patient with spinocerebellar ataxia type 12

    YM. Sun, LQ. Lang, B. Shen, J. Hu, JJ. Wu (Shanghai, China)

    Objective: To treat the medication-resistant tremor of SCA12 by Deep brain stimulation (DBS) Background: Action tremor might be the most prominent feature of SCA12 patient…
  • 2024 International Congress

    4-Aminopyridine improves downbeat nystagmus in SCA27b: A case report

    S. Coulette, M. Philibert, JM. Trocello, B. Gaymard, C. Desjardins (Paris, France)

    Objective: To assess objective clinical improvement in video-oculography in a patient with SCA27b on 4-aminopyridine (4-AP) treatment. Background: Spinocerebellar ataxia 27b (SCA27b; MIM 620174) is…
  • 2024 International Congress

    Dentate Deep Brain Stimulation for Cerebellar Ataxia: Long Term Outcomes

    C. França, J. Diniz, I. Paraguay, D. de Andrade, V. Silva, R. Galhardoni, M. Teixeira, E. Barbosa, R. Cury (São Paulo, Brazil)

    Objective: To evaluate long-term results of Deep Brain Stimulation (DBS) targeting the dentate nucleus (DN) in patients with cerebellar ataxia Background: Cerebellar ataxia remains a…
  • 2024 International Congress

    Ataxia and Gait Improvement in Relapsing-Remitting Multiple Sclerosis After Transcranial Magnetic Stimulation (TMS): A Case Study

    NA. Megayasa, A. Tiksnadi, D. Tunjungsari (Jakarta Pusat, Indonesia)

    Objective: To evaluate the effectiveness of Transcranial Magnetic Stimulation (TMS) in improving ataxia and gait in a patient with Relapsing-Remitting Multiple Sclerosis (RRMS). Background: Multiple…
  • 2024 International Congress

    Evaluating Pharmacological Interventions for Friedreich Ataxia: A Network Meta-Analysis of Randomised Trials

    T. Dave, V. Kumar, R. Raj, MA. Shamim, V. Suresh, K. Patel, M. Hassan, A. Bhonsale, DVV. Krishna, B. Dhakal, A. Ambulinambi, D. Dey (Chernivtsi, Ukraine)

    Objective: To compare the clinical efficacy of different pharmacological agents in reduction of disease severity of Friedreich Ataxia. Background: Friedreich ataxia is a rare, inherited,…
  • 2023 International Congress

    The role of Anti-Ribosomal P antibody in Autoimmune cerebellar ataxia

    V. Vysakha (Trivandrum, India)

    Objective: To describe the clinical features and presentation of an auto-immune cerebellar ataxia with asymmetric Holmes tremor and its therapeutic response. Background: Autoimmune cerebellar ataxia…
  • 2023 International Congress

    Dance for Parkinson’s disease to improve gait and balance: clinical assessments vs. objective measures.

    HHN. Kalyani, K. Sullivan, G. Moyle, S. Brauer, E. Jeffrey, G. Kerr (Colombo, Sri Lanka)

    Objective: To evaluate how the dance classes based on the Dance for Parkinson’s Disease®(DfPD®) model could improve gait and balance in people with Parkinson’s disease…
  • 2023 International Congress

    Effectiveness of non-invasive therapy of tPCS & peripheral nerve stimulation on Ataxia patients

    D. Heng, C. Chen, X. Choi, E. Lim, G. Chia, W. Li, K. Narasimhalu, P. Kumar, Y. Lo, E. Tan (Singapore, Singapore)

    Objective: A pilot study to determine the effectiveness of a combination of transcranial pulsed current stimulation and pulsed current peripheral nerve stimulation as a novel…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 9
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley